Program
Fenretinide
Also written as “LAU-7b”, “LAU-7b for 3 cycles” and “ISLA101”.
Its studies are mostly in Lymphoma, T-Cell · Small Cell Lung Carcinoma · Post-Acute COVID-19 Syndrome · Inflammation · Dengue, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laurent Pharmaceuticals | 30 open or running | phase 3since May 28, 2020 | Feb 21, 2017 | none ahead |
| Island Pharmaceuticals | 20 open or running | phase 2since Jul 15, 2024 | Oct 25, 2023 | none ahead |
| SciTech Development | 22 open or running | phase 1since Jan 13, 2020 | Jan 13, 2020 | May 1, 2027phase 1 · NCT06922539 |
| CerRx | 10 open or running | phase 2since Jul 7, 2015 | Jul 7, 2015 | none ahead |
| Sirion Therapeutics | 10 open or running | phase 2since Jan 30, 2007 | Jan 30, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 30, 2007First study: phase 2 study in Geographic AtrophyNew to Sirion TherapeuticsSirion Therapeutics · NCT00429936 · 245 enrolled
- Jul 7, 2015CerRx's first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to CerRxCerRx · NCT02495415 · 140 enrolled · United States
- Feb 21, 2017Laurent Pharmaceuticals's first study: phase 2 study in Cystic FibrosisNew to Laurent PharmaceuticalsLaurent Pharmaceuticals · NCT03265288 · 166 enrolled · United States, Australia, Canada
- Jan 13, 2020SciTech Development's first study: phase 1 study in Lymphoma, T-CellNew to SciTech DevelopmentSciTech Development · NCT04234048 · 46 planned · United States
- May 28, 2020Phase 3 study in InflammationLaurent Pharmaceuticals · NCT04417257 · 351 enrolled · United States, Canada
- Aug 11, 2023Phase 3 study in Post-Acute COVID-19 SyndromeLaurent Pharmaceuticals · NCT05999435 · 272 enrolled · Canada
- Oct 25, 2023Island Pharmaceuticals's first study: phase 1 study in Safety and TolerabilityNew to Island PharmaceuticalsIsland Pharmaceuticals · NCT06181760 · 25 enrolled · Australia
- Jul 15, 2024Phase 2 study in DengueIsland Pharmaceuticals · NCT06528457 · 15 enrolled · United States
- Mar 22, 2025Phase 1 study in Small Cell Lung CarcinomaSciTech Development · NCT06922539 · 44 planned · United States
Ahead
- May 1, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaSciTech Development · NCT06922539
- Jun 1, 2028Primary completion: phase 1 study in Lymphoma, T-CellSciTech Development · NCT04234048
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06922539Small Cell Lung Carcinoma · United States | 1 | Recruiting | SciTech Development | May 1, 2027 | 44 |
| NCT06528457Dengue · United States | 2 | Completed | Island Pharmaceuticals | May 21, 2025 | 15 |
| NCT06181760Safety and Tolerability · Australia | 1 | Completed | Island Pharmaceuticals | Feb 13, 2024 | 25 |
| NCT05999435Post-Acute COVID-19 Syndrome · Canada | 3 | Completed | Laurent Pharmaceuticals | Aug 5, 2024 | 272 |
| NCT04417257Inflammation · United States, Canada | 3 | Terminated | Laurent Pharmaceuticals | Feb 15, 2024 | 351 |
| NCT04234048Lymphoma, T-Cell · United States | 1 | Recruiting | SciTech Development | Jun 1, 2028 | 46 |
| NCT03265288Cystic Fibrosis · United States, Australia, Canada | 2 | Completed | Laurent Pharmaceuticals | Sep 15, 2021 | 166 |
| NCT02495415Lymphoma, T-Cell, Peripheral · United States | 2 | UNKNOWN | CerRx | Jul 2021 | 140 |
| NCT00429936Geographic Atrophy | 2 | Completed | Sirion Therapeutics | May 2010 | 245 |
How it is read
Names in the registry
- “Fenretinide”, 6 entries
- “LAU-7b”, 2 entries
- “LAU-7b for 3 cycles”, 1 entry
- “ISLA101”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, 1 study
- Small Cell Lung Carcinoma, 1 study
- Post-Acute COVID-19 Syndrome, 1 study
- Inflammation, 1 study
- Dengue, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.